PMID- 25229783
OWN - NLM
STAT- MEDLINE
DCOM- 20141114
LR  - 20151119
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Linking)
VI  - 40
IP  - 10
DP  - 2014 Oct
TI  - A retrospective review and observational study of outcomes and safety of 
      bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis.
PG  - 1118-24
LID - 10.1097/01.DSS.0000452658.83001.d9 [doi]
AB  - BACKGROUND: The efficacy and safety of bimatoprost ophthalmic solution 0.03% for 
      treating hypotrichosis were shown in a randomized controlled trial and in an 
      open-label study. To date, no data on real-world experience have been published. 
      OBJECTIVE: To evaluate long-term patient satisfaction, usage patterns, and safety 
      of bimatoprost 0.03% in clinical practice. MATERIALS AND METHODS: In this 
      retrospective chart review with a cross-sectional design, adult patients exposed 
      to bimatoprost 0.03% for at least 12 months were randomly sampled from 16 
      investigational sites. Charts were reviewed for medication usage characteristics 
      and adverse events (AEs). At a study visit, questionnaires eliciting 
      patient-reported outcomes were administered and spontaneously reported AEs were 
      tabulated. RESULTS: Analysis included 585 subjects with a mean (SD) treatment 
      duration of 19.3 (4.3) months. Patient satisfaction with bimatoprost 0.03% was 
      92.5%; on average, approximately 3 applications per week maintained benefits. 
      Overall, 27.4% of patients spontaneously recalled experiencing AEs while on 
      treatment; however, patient charts showed that only 4 AEs were documented. No 
      instances of iris hyperpigmentation occurred. No serious or severe AEs were 
      noted. CONCLUSION: Treatment with bimatoprost 0.03% for at least 12 months is 
      safe, and long-term use is associated with a high degree of satisfaction.
FAU - Yoelin, Steven G
AU  - Yoelin SG
AD  - *Medical Associates Inc., Newport Beach, California; daggerPrivate Practice, Boca 
      Raton, Florida; double daggerDepartment of Dermatology, School of Medicine, University of 
      North Carolina, Chapel Hill, Chapel Hill, North Carolina;  section signAesthetic Solutions, 
      Chapel Hill, North Carolina;  ||Allergan, Inc., Irvine, California;  paragraph signSCI Scientific 
      Communications and Information, Parsippany, New Jersey.
FAU - Fagien, Steven
AU  - Fagien S
FAU - Cox, Sue Ellen
AU  - Cox SE
FAU - Davis, Paula G
AU  - Davis PG
FAU - Campo, Antoinette
AU  - Campo A
FAU - Caulkins, Carrie A
AU  - Caulkins CA
FAU - Gallagher, Conor J
AU  - Gallagher CJ
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
RN  - 0 (Amides)
RN  - 0 (Ophthalmic Solutions)
RN  - 4208238832 (Cloprostenol)
RN  - QXS94885MZ (Bimatoprost)
SB  - IM
MH  - Adult
MH  - Amides/adverse effects/*therapeutic use
MH  - Bimatoprost
MH  - Cloprostenol/adverse effects/*analogs & derivatives/therapeutic use
MH  - Cross-Sectional Studies
MH  - Erythema/chemically induced
MH  - *Eyelashes
MH  - Eyelid Diseases/chemically induced
MH  - Female
MH  - Humans
MH  - Hypotrichosis/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Ophthalmic Solutions/adverse effects/*therapeutic use
MH  - *Patient Satisfaction
MH  - Pigmentation Disorders/chemically induced
MH  - Pruritus/chemically induced
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2014/09/18 06:00
MHDA- 2014/11/15 06:00
CRDT- 2014/09/18 06:00
PHST- 2014/09/18 06:00 [entrez]
PHST- 2014/09/18 06:00 [pubmed]
PHST- 2014/11/15 06:00 [medline]
AID - 10.1097/01.DSS.0000452658.83001.d9 [doi]
PST - ppublish
SO  - Dermatol Surg. 2014 Oct;40(10):1118-24. doi: 10.1097/01.DSS.0000452658.83001.d9.